Twist Bioscience Corporation – NASDAQ:TWST
Founder-led company
Twist Bioscience stock price today
$28.432
-19.73
-40.98%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 2 days
Twist Bioscience stock price monthly change
-9.86%
month
Twist Bioscience stock price quarterly change
-9.86%
quarter
Twist Bioscience stock price yearly change
+25.97%
year
Twist Bioscience key metrics
Market Cap | 2.77B |
Enterprise value | 545.49M |
P/E | -3.41 |
EV/Sales | 2.52 |
EV/EBITDA | -2.72 |
Price/Sales | 3.55 |
Price/Book | 1.02 |
PEG ratio | 0.12 |
EPS | -3.65 |
Revenue | 266.16M |
EBITDA | -187.91M |
Income | -208.28M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | -99.23% |
Oper. margin | -105.47% |
Gross margin | 43.59% |
EBIT margin | -105.47% |
EBITDA margin | -70.6% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeTwist Bioscience stock price history
Twist Bioscience stock forecast
Twist Bioscience financial statements
| Mar 2023 | 60.18M | -59.15M | -98.3% |
|---|---|---|---|
| Jun 2023 | 63.74M | -57.39M | -90.05% |
| Sep 2023 | 66.94M | -46.24M | -69.08% |
| Mar 2024 | 75.30M | -45.49M | -60.41% |
| Sep 2025 | 92.21M | -37.46M | -40.63% |
|---|---|---|---|
| Oct 2025 | 94.12M | -34.15M | -36.28% |
| Mar 2026 | 285M | 0 | |
| Mar 2026 | 300M | 0 |
Analysts Price target
Financials & Ratios estimates
| Mar 2023 | 853924000 | 149.99M | 17.57% |
|---|---|---|---|
| Jun 2023 | 810332000 | 152.78M | 18.85% |
| Sep 2023 | 776403000 | 152.97M | 19.7% |
| Mar 2024 | 702846000 | 142.71M | 20.31% |
| Mar 2023 | -44.28M | 41.16M | 1.52M |
|---|---|---|---|
| Jun 2023 | -23.41M | 18.67M | -661K |
| Sep 2023 | -20.70M | -2.24M | 442K |
| Mar 2024 | -19.42M | -5.24M | 1.82M |
Twist Bioscience alternative data
| Aug 2023 | 810 |
|---|---|
| Sep 2023 | 810 |
| Oct 2023 | 810 |
| Nov 2023 | 810 |
| Dec 2023 | 810 |
| Jan 2024 | 810 |
| Feb 2024 | 810 |
| Mar 2024 | 810 |
| Apr 2024 | 810 |
| May 2024 | 810 |
| Jun 2024 | 919 |
| Jul 2024 | 919 |
Twist Bioscience other data
72.96%
-27.04%
of TWST is owned by hedge funds
126
-64
41.18M
-19.58M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Feb 2024 | 0 | 4110 |
| Mar 2024 | 0 | 5182 |
| Apr 2024 | 0 | 5039 |
| May 2024 | 0 | 12243 |
| Jun 2024 | 0 | 6202 |
| Jul 2024 | 0 | 5087 |
| Aug 2024 | 0 | 10851 |
| Sep 2024 | 0 | 6122 |
| Oct 2024 | 0 | 30001 |
| Nov 2024 | 0 | 68456 |
| Dec 2024 | 0 | 3669 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | CHO DENNIS officer: See Remarks | Common Stock | 367 | $52.7 | $19,342 | ||
Sale | GREEN PAULA officer: SVP of Human Resources | Common Stock | 860 | $52.7 | $45,325 | ||
Sale | LEPROUST EMILY M. director, officer.. | Common Stock | 2,216 | $52.7 | $116,792 | ||
Sale | WERNER ROBERT F. officer: Chief Ac.. | Common Stock | 226 | $52.7 | $11,911 | ||
Sale | WERNER ROBERT F. officer: Chief Ac.. | Common Stock | 789 | $44.2 | $34,871 | ||
Option | CHESS ROBERT director | Common Stock | 3,600 | $8.82 | $31,752 | ||
Sale | CHESS ROBERT director | Common Stock | 2,324 | $46.99 | $109,202 | ||
Sale | CHESS ROBERT director | Common Stock | 1,276 | $47.76 | $60,935 | ||
Option | CHESS ROBERT director | Stock Option (right to buy) | 3,600 | $8.82 | $31,752 | ||
Sale | CHO DENNIS officer: See Remarks | Common Stock | 1,507 | $48 | $72,333 |
| Patent |
|---|
Application Filling date: 18 May 2022 Issue date: 8 Sep 2022 |
Application Filling date: 17 Feb 2022 Issue date: 1 Sep 2022 |
Application Filling date: 20 Jan 2022 Issue date: 18 Aug 2022 |
Grant Filling date: 11 Sep 2018 Issue date: 9 Aug 2022 |
Application Filling date: 15 Apr 2022 Issue date: 4 Aug 2022 |
Application Filling date: 9 Dec 2021 Issue date: 4 Aug 2022 |
Grant Filling date: 12 Dec 2019 Issue date: 5 Jul 2022 |
Application Filling date: 21 Oct 2021 Issue date: 30 Jun 2022 |
Grant Filling date: 19 Jun 2020 Issue date: 17 May 2022 |
Grant Filling date: 20 May 2020 Issue date: 17 May 2022 |
| Quarter | Transcript |
|---|---|
| Q2 2024 2 May 2024 | Q2 2024 Earnings Call Transcript |
| Q1 2024 2 Feb 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 17 Nov 2023 | Q4 2023 Earnings Call Transcript |
| Q3 2023 4 Aug 2023 | Q3 2023 Earnings Call Transcript |
Twist Bioscience: Strong Performance In A Soft Market
A New Look At Twist Bioscience
Twist Bioscience: Progress Hidden By Execution Issues And Soft Demand
Reconsidering Twist Biosciences
Biopharma Exposure In SVB Financial Group And Investor Strategy
23andMe Looking Promising For The Long Term
Twist And Short
Twist Bioscience: DNA Synthesis Leader Appealing 'Picks And Shovels' Play
Biopharmaceutical Stocks Continue To Perform Well, With Many Attractive Values Remaining
-
What's the price of Twist Bioscience stock today?
One share of Twist Bioscience stock can currently be purchased for approximately $28.43.
-
When is Twist Bioscience's next earnings date?
Unfortunately, Twist Bioscience's (TWST) next earnings date is currently unknown.
-
Does Twist Bioscience pay dividends?
No, Twist Bioscience does not pay dividends.
-
How much money does Twist Bioscience make?
Twist Bioscience has a market capitalization of 2.77B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 27.69% to 312.97M US dollars.
-
What is Twist Bioscience's stock symbol?
Twist Bioscience Corporation is traded on the NASDAQ under the ticker symbol "TWST".
-
What is Twist Bioscience's primary industry?
Company operates in the Healthcare sector and Medical - Diagnostics & Research industry.
-
How do i buy shares of Twist Bioscience?
Shares of Twist Bioscience can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Twist Bioscience's key executives?
Twist Bioscience's management team includes the following people:
- Dr. Emily Marine Leproust Ph.D. Co-Founder, Chairman, Pres & Chief Executive Officer(age: 52, pay: $1,280,000)
- Mr. Patrick Weiss Chief Operating Officer(age: 54, pay: $786,410)
- Mr. James M. Thorburn Chief Financial Officer(age: 69, pay: $771,710)
- Dr. Patrick John Finn Ph.D. Chief Commercial Officer(age: 53, pay: $726,350)
- Dr. William Charles Banyai Ph.D. Senior Vice President of Advanced Devel., GM of Data Storage & Director(age: 70, pay: $628,120)
-
Is Twist Bioscience founder-led company?
Yes, Twist Bioscience is a company led by its founder Dr. Emily Marine Leproust Ph.D..
-
How many employees does Twist Bioscience have?
As Jul 2024, Twist Bioscience employs 919 workers, which is 13% more then previous quarter.
-
When Twist Bioscience went public?
Twist Bioscience Corporation is publicly traded company for more then 6 years since IPO on 31 Oct 2018.
-
What is Twist Bioscience's official website?
The official website for Twist Bioscience is twistbioscience.com.
-
Where are Twist Bioscience's headquarters?
Twist Bioscience is headquartered at 681 Gateway Boulevard, South San Francisco, CA.
-
How can i contact Twist Bioscience?
Twist Bioscience's mailing address is 681 Gateway Boulevard, South San Francisco, CA and company can be reached via phone at +800 7190671.
Twist Bioscience company profile:
Twist Bioscience Corporation
twistbioscience.comExchange:
NASDAQ
Full time employees:
919
Industry:
Medical - Diagnostics & Research
Sector:
Healthcare
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has collaboration agreements with Victorian Clinical Genetic Services; Vivlion GmbH.; Kyowa Kirin Pharmaceutical Research, Inc.; deepCDR Biologics AG; and Centogene N.V to develop advanced sequencing tools. It also has a research collaboration with Boehringer Ingelheim International GmbH to use proprietary antibody libraries to discover therapeutic antibodies against multiple targets. Twist Bioscience Corporation was incorporated in 2013 and is headquartered in South San Francisco, California.
681 Gateway Boulevard
South San Francisco, CA 94080
South San Francisco, CA 94080
CIK: 0001581280
ISIN: US90184D1000
CUSIP: 90184D100
